Golden Drugs Private Limited, a amalgamated private limited company, was established on 27 August 2012 in Bangalore, Karnataka, India. Engaging in api manufacturers within the manufacturing sector, it holds CIN: U24232KA2012PTC157474. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹4.50 Cr and a paid-up capital of ₹3.59 Cr.
Formerly known as Golden Drug Private Limited. It upholds a compliant status. Employing 80 professional, Its leadership includes Ravindrakumar Kothari (Director), Shailesh Dheerajmal Siroya (Director). Past directors included Ravindrakumar Kothari, Gulshan Jain Dalal, Snehlata Dalal. It holds ₹20.00 Cr open charges and ₹24.50 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 10/1, Laxmi Narayan Complex, 5Th Floor, Palace Road,, Bangalore, Karnataka, 560052.
U24232KA2012PTC157474
157474
27 August 2012
₹4.50 Cr
₹3.59 Cr
Roc Bangalore
Unlisted
Amalgamated
Explore comprehensive insights into Golden Drugs Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ravindrakumar Kothari | Director | 15 Nov 2018 | Current |
| Shailesh Dheerajmal Siroya | Director | 12 Apr 2018 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 30 Sep 2019 | Past |
| Pramod Abcsdd | Director | 21 Jul 2016 | Past |
| Pramod Abcsdd | Director | 22 Mar 2018 | Past |
| Pramod Abcsdd | Director | 19 Nov 2018 | Past |
| Pramod Abcsdd | Director | 06 May 2016 | Past |
| Pramod Abcsdd | Director | 19 Nov 2018 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Golden Drugs Private Limited, for the financial year ended 2024, experienced significant reduction in revenue, with a 21.62% decrease. The company also saw a slight improvement in profitability, with a 8.67% increase in profit. The company's net worth observed a substantial decline by a decrease of 38.54%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2024, Golden Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹200,000,000.00
₹245,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Sep 2018 | Tata Capital Financial Services Limited | ₹15.00 Cr | Satisfied |
| 15 Oct 2014 | Punjab National Bank | ₹4.00 Cr | Satisfied |
| 15 Oct 2014 | Punjab National Bank | ₹5.50 Cr | Satisfied |
Explore comprehensive loan charge details -
Golden Drugs has a workforce of 80 employees as of Mar 08, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Golden Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Golden Drugs's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Golden Drugs Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Golden Drugs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Bangalore. was recorded as a recent event.
The activity A charge registered on 28 Sep 2018 via Charge ID 100207862 with Tata Capital Financial Services Limited was fully satisfied on 24 Jan 2024. was completed.
The activity Ravindrakumar Kothari was appointed as a Director was appointed as a Director on 15 Nov 2018 & has been associated with this company since 7 years 1 month . was completed.
A charge with Tata Capital Financial Services Limited of Rs. 15.00 Cr registered on 28 Sep 2018 with Charge ID 100207862 was modified on 17 Oct 2018. was recorded as a recent event.
A charge with Tata Capital Financial Services Limited amounted to Rs. 15.00 Cr with Charge ID 100207862 was registered on 28 Sep 2018. was recorded as a recent event.
The CIN of Golden Drugs Private Limited is U24232KA2012PTC157474.
Golden Drugs Private Limited is headquartered at 10/1, Laxmi Narayan Complex, 5Th Floor, Palace Road,, Bangalore, Karnataka, 560052.
Golden Drugs Private Limited was incorporated on 27 August 2012.
The current directors of Golden Drugs Private Limited are
The primary industry of Golden Drugs Private Limited is Manufacturing.
Golden Drugs Private Limited is unlisted.
The authorized capital of Golden Drugs Private Limited is ₹4.50 Cr, and the paid-up capital is ₹3.59 Cr.
The compliance status of Golden Drugs Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX